-
-
Editor's Choice -
Pharma & Human Health -
Finance -
Pharma & Human Health
Editor’s Choice
Editor's Choice
Multi-strain probiotic therapy shows promise in preventing bacterial vaginosis recurrence
A global team of experts has identified a promising new approach to prevent recurrence of bacterial vaginosis (BV), a condition that affects millions of women worldwide. In a phase 1 randomized clinical trial of women […]
Editor's Choice
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. […]
Editor's Choice
Immunity as a Lifestyle Priority
Immune health has evolved from a seasonal concern to an essential part of everyday well-being. Consumers are adopting proactive strategies that combine healthy lifestyle habits with advanced biotic solutions, driving innovation across the supplement industry. […]
In Case you Missed it:
Pharma & Human Health
Missing microbes in UK infant gut and probiotics highlighted by global microbiome atlas
A global atlas mapping two key gut bacteria in infants around the world has uncovered a treasure trove of bacterial strains adapted to the infant gut and not found in commercial probiotic products. It lays […]
Pharma & Human Health
How Oral Drugs and Nutrition impacts Microbiome: Realistic Dynamic In Vitro Microbiome Modeling
Not so long ago the gut microbiome was considered a scientific curiosity. Today it’s impossible to ignore. The trillions of microorganisms living in our gastrointestinal tract influence digestion, immunity, metabolism and even mental health. When […]
Pharma & Human Health
Global scientific paper establishes first consensus definition of gut health
Gut health has become a familiar term in both scientific papers and marketing campaigns. Although scientists generally agree that gut health is a key component of overall health and wellness, the concept of gut health […]
Editor's Choice
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive results in its Phase 1b First-in-Human trial, COMPOSER-1, of MB310 in ulcerative colitis (UC) patients. […]
Editor's Choice
Immunity as a Lifestyle Priority
Immune health has evolved from a seasonal concern to an essential part of everyday well-being. Consumers are adopting proactive strategies that combine healthy lifestyle habits with advanced biotic solutions, driving innovation across the supplement industry. […]
Pharma & Human Health
‘GABA Factory’ Probiotic LP815® Improves Sleep and Reduces Stress
Verb Biotics U.S. Consumer Health Survey of 2,000 adults reported that 73% of consumers experience symptoms related to mental health, including stress and poor sleep. Among these, 40% said their symptoms affect daily functioning, highlighting […]
Pharma & Human Health
EnteroBiotix announces positive Phase 2 results for potential first-in-class, oral, full-spectrum microbiome therapy for IBS
EnteroBiotix, a clinical-stage biopharmaceutical company focused on developing best-in-class therapies for gut health, today announced positive final results from TrIuMPH, a Phase 2a clinical trial evaluating EBX-102-02, a next-generation oral full-spectrum microbiome therapeutic, in patients […]
Pharma & Human Health
AOB Pharma receives EMA positive decision on the Pediatric Investigation Plan for development of B244
AOB Pharma, Inc. (“AOBiome”), a leading clinical-stage biotechnology company focusing on inflammatory skin conditions with their lead asset B244 for the treatment of mild to moderate atopic dermatitis (AD) and pruritus, received a positive decision […]
